Therapeutics(27)
-
MMP14 targeting natural antibodies to treat ovarian cancer (No. T4-2152)
MMP14 is a major antibody target on the tumor cell surface as it is highly expressed on tumor cells and plays a key role in cancer progression and metastasis. Natural occurring autoantibodies targeting MMP14 were isolated from ovarian cancer patients. ... Read more17825 -
Novel Combination Therapy For Improved Management of Depression (No. T4-2129)
A novel combination therapy pairing ketamine with retigabine, an FDA-approved KCNQ channel activator, offers a promising strategy for mood-related disorders. ... Read more6097 -
Modulating Weight Gain and Loss by Understanding the Mechanism of Smoking Related Weight Changes (No. T4-2078)
A new approach to prevent weight gain during smoking cessation (SCWG) focuses on the gut microbiome and metabolites like dimethylglycine (DMG) and acetylglycine (ACG). ... Read more17357 -
Enhanced Anti-PD-L1 Immunotherapy (No. T4-2059)
A novel approach for enhancing the efficacy of PD-L1 targeting antibodies by harnessing beneficial FcγR signaling pathways. Strategy involves either (1) Co-administration of PD-L1 targeting antibodies with an FcγRIIB-blocking antibody or ... Read more17039 -
Covalent Chemistry Platform for Diagnostics and Drug Discovery (No. T4-2045)
CoLDR (Covalent Ligand-Directed Release) chemistry enables site-specific covalent labeling and activation of endogenous proteins using small-molecule covalent ligands. ... Read more6106 -
Safer CAR-T Cell Platform (No. T4-2033)
A platform for engineering CAR-T cells with enhanced cancer-killing ability and reduced toxicity. By redesigning the transmembrane domain of the CAR using a computational protein design platform, researchers created synthetic receptors that form stable, specific oligomeric structures. ... Read more6124 -
AI-Driven Discovery Platform for Immune Protein Inhibitors (No. T4-2027)
There is a growing need for innovative strategies to selectively target key drivers of immune-mediated diseases. ... Read more19381 -
Small Molecules for Treatment of Huntington's Disease and Related Disorders (No. T4-1947)
A new class of small molecules offers a targeted strategy for treating Huntington’s disease (HD) and related trinucleotide repeat expansion disorders (TREDs). ... Read more6193 -
New Antiviral Drugs from Bacterial Natural Products (No. T4-1934)
There is a growing need for effective antiviral therapies, particularly for viruses that currently lack approved treatments. ... Read more12514 -
Anti-LOX for the Treatment of Duchenne, Fibrosis and Cancer (No. T4-1913)
LOX is a key driver of fibrosis and tumor progression through its role in extracellular matrix remodeling. We developed a set of LOX inhibitors based on LOX’s natural prodomain (LPD) to treat fibrosis, Duchenne Muscular Dystrophy (DMD), and cancer. ... Read more6026
Pages
